Dergiler / European Archives of Medical Research / 2021 / Cilt: 37 - Sayı: 3

Optical Coherence Tomography Findings in Patients with Myotonic Dystrophy Type 1

Sayfa
178–182
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

No correlation was found between CMT, SFCT, and the MIR stages (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Myotonic dystrophy type 1 (DM1) is characterized by myotonia and progressive muscle weakness caused by the cytosine-thymineguanine trinucleotide repeat and is the most common muscular dystrophy in adults.
📊
Temel Bulgular & Veri:Although various ocular abnormalities, particularly cataracts, are well known in patients with DM1, few studies and case reports are available on retinal involvement, such as retinal degeneration, the epiretinal membrane (ERM), and macular degeneration.
💡
Sonuç & Katkı:No correlation was found between CMT, SFCT, and the MIR stages (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Myotonic dystrophy type 1 (DM1) is characterized by myotonia and progressive muscle weakness caused by the cytosine-thymineguanine trinucleotide repeat and is the most common muscular dystrophy in adults. Although various ocular abnormalities, particularly cataracts, are well known in patients with DM1, few studies and case reports are available on retinal involvement, such as retinal degeneration, the epiretinal membrane (ERM), and macular degeneration. In this study, we investigated the retinal involvement findings using optical coherence tomography (OCT) in patients who were followed up in the neuromuscular outpatient clinic with a diagnosis of DM1. Methods: In this prospective cross-sectional study, 20 patients with genetically confirmed DM1 aged 18-65 years were included. The control group was formed from healthy individuals of a similar age and gender distribution to the patient group. Patients with diabetes mellitus, diabetic retinopathy, glaucoma, and previous cataract surgery were excluded from the study. Muscular impairment rating (MIR) scales were evaluated according to the distribution findings of myotonia and muscle weakness on a neurological examination. Patients were evaluated with OCT to examine macular and optic nerve morphology after ophthalmologic and fundus examinations were performed by a retinal specialist. Results: The mean central macular thickness (CMT) values were 275.52±40.31 and 262.76±9.06 in the control and study groups, respectively (p=0.09). Subfoveal choroidal thicknesses (SFCT) were significantly higher in the study group (341.8±95.04 vs. 279.59±46.65; p=0.002). The mean retinal nerve fiber layer did not differ between the groups (103.6±14 vs. 101.3±12; p=0.12). No ERM was detected in any of the DM1 patients. No correlation was found between CMT, SFCT, and the MIR stages (p

🔖

Bu Makaleye Atıf Yap

ERDEN, B., AKAN, O. (2022). Optical Coherence Tomography Findings in Patients with Myotonic Dystrophy Type 1. European Archives of Medical Research, Cilt: 37 - Sayı: 3, 178–182. https://ajindex.com/articles/510347

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Smith CA, Gutmann L. Myotonic Dystrophy Type 1 Management and Therapeutics. Curr Treat Options Neurol 2016;18:52
  2. Thornton CA. Myotonic dystrophy. Neurol Clin 2014;32:705-19
  3. Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 2001;56:336-40
  4. Kersten HM, Roxburgh RH, Child N, Polkinghorne PJ, Frampton C, Danesh-Meyer HV. Epiretinal membrane: a treatable cause of visual disability in myotonic dystrophy type 1. J Neurol 2014;261:37-44
  5. Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010;24:1743-56
  6. Yazgan S, Arpaci D, Celik HU, Dogan M, Isık I. Macular Choroidal Thickness May Be the Earliest Determiner to Detect the Onset of Diabetic Retinopathy in Patients with Prediabetes: A Prospective and Comparative Study. Curr Eye Res 2017;42:1039-47
  7. Bolukbasi S, Erden B, Cakir A, Bayat AH, Elcioglu MN, Yurttaser Ocak S, et al. Pachychoroid Pigment Epitheliopathy and Choroidal Thickness Changes in Coeliac Disease. J Ophthalmol 2019;2019:6924191
  8. Kurt MM, Akpolat C, Evliyaoglu F, Yilmaz M, Ordulu F. Evaluation of Retinal Neurodegeneration and Choroidal Thickness in Patients with Inactive Graves’ Ophthalmopathy. Klin Monbl Augenheilkd 2021 Mar 17. English
  9. Choi MG, Chung H, Yoon YH, Kim JT. Effects of Systemic Profiles on Choroidal Thickness in Treatment-Naïve Eyes With Diabetic Retinopathy. Invest Ophthalmol Vis Sci 2020;61:12
  10. Okamoto M, Yamashita M, Ogata N. Effects of intravitreal injection of ranibizumab on choroidal structure and blood flow in eyes with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2018;256:885-92
  11. Alsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, et al. Diabetes, metformin and cancer risk in myotonic dystrophy type I. Int J Cancer 2020;147:785-92
  12. Ikeda KS, Iwabe-Marchese C, França MC Jr, Nucci A, Carvalho KM. Myotonic dystrophy type 1: frequency of ophthalmologic findings. Arq Neuropsiquiatr 2016;74:183-8
  13. Kimizuka Y, Kiyosawa M, Tamai M, Takase S. Retinal changes in myotonic dystrophy. Clinical and follow-up evaluation. Retina 1993;13:129-35
  14. Hayasaka S, Kiyosawa M, Katsumata S, Honda M, Takase S, Mizuno K. Ciliary and retinal changes in myotonic dystrophy. Arch Ophthalmol 1984;102:88-93
  15. Ng CH, Cheung N, Wang JJ, Islam AF, Kawasaki R, Meuer SM, et al. Prevalence and risk factors for epiretina